This Stock Has Bottomed 这只股票已经触底

After dropping 93% from all time high (20) to all time low (1.25),  HOOK made a big come back today by surging almost 62% with 364 times average volume changing hand. Today's surge in price caused stock to recovered above its 20 and 50 day moving averages on the daily chart. This means HOOK's short and intermediate trends are now up. On the weekly chart, I see prices which HOOK is going to challenge are 3, 5 and 7. Followings are positives for HOOK:

1. Today's news is the announcement of an agreement between HOOK and GILD for advancing the HIV program through the end of a Phase 1b clinical trial. HOOK will receive a $15 million upfront fee with the amended agreement. It will also receive a $5M equity payment investment from Gilead (GILD) and up to $30M in additional equity financing. These amounts are significant since HOOK's annual revenue is only 19.7 millions. 

2. There are 7 drugs in HOOK's research pipeline. Merk(MRK) and Gilead (GILD) are two major drug makers that HOOK is working with.

3. HOOK is a value play since its book value is 3.29 and cash is 2.59 per share and negligible debt. 

4. HOOK can move fast because it only has 23.54 million shares float, institutions are holding 72% and there are 10.47% shorts.

5. Analysts consensus rating is Strong Buy with 8.37 price target.

HOOKIPA (HOOK 2.07) is responsible for advancing the HIV HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16- positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York , New York.

在从历史最高点 (20) 下跌 93% 至历史最低点 (1.25) 之后，HOOK 今天以 364 倍的平均交易量换手，飙升近 62%，强势回归。今天的价格飙升导致股票在日线图上回升至其 20 日和 50 日移动平均线之上。这意味着 HOOK 的短期和中期趋势现在已经是上涨。在周线图上，我看到 HOOK 将挑战的价格是 3、5 和 7。以下是 HOOK 的正面因素：

1. 今天的新闻是 HOOK 和 GILD 之间宣布达成一项协议，以推进 HIV 计划直至 1b 期临床试验结束。协议称HOOK 将获得 1500 万美元的预付费用。它还将获得来自吉利德 (GILD) 的 500 万美元股权支付投资和高达 3000 万美元的额外股权融资。由于 HOOK 的年收入仅为 1970 万美元，因此这些金额是非常可观的。

2. HOOK在研药物有7个。 Merk (MRK) 和 Gilead (GILD) 是 HOOK 正在与之合作的两家主要制药商。

3. HOOK 是只价值股，因为其账面价值为 3.29，现金为每股 2.59及可忽略的债务。

4. HOOK可以上升得快因为它只有2354万股流通股，机构持股72%，空头10.47%。

5. 分析师一致评级为强力买入，目标价为 8.37。

HOOKIPA（HOOK 2.07）负责推进HIV HOOKIPA Pharma Inc.，一家临床阶段的生物制药公司，基于其专有的沙粒病毒平台开发针对传染病和癌症的免疫疗法。 该公司研发的主要传染病产品是 HB-101，这是一项随机双盲 II 期临床试验，用于等待巨细胞病毒阳性供体肾移植的患者。 其主要的肿瘤学产品是 HB-201和 HB-202，它们正在 I/II 期临床试验中用于治疗人乳头瘤病毒 16 阳性癌症。 该公司与 Gilead Sciences, Inc. 合作开发传染病候选产品，旨在支持慢性乙型肝炎病毒和人类免疫缺陷病毒感染的功能性治疗。 HOOKIPA Pharma Inc. 成立于 2011 年，总部位于纽约州纽约市。